PM 1021
Alternative Names: PM-1021Latest Information Update: 19 Dec 2023
At a glance
- Originator Biotheus
- Developer Adimab; Biotheus
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Dec 2023 Discontinued - Phase-I for Cancer in China (Parenteral)
- 11 Oct 2022 Phase-I clinical trials in Cancer in China (Parenteral) (Biotheus pipeline, October 2022).
- 14 Sep 2022 Biotheus plans a phase I trial for Solid tumours (Late-stage disease, Monotherapy, Combination therapy) in Australia in December 2022 (NCT05537051)